VANCOUVER, Feb. 22 /CNW/ - Protox Therapeutics Inc. (the "Company" or
 "Protox") (TSX: PRX), a leader in the development of receptor targeted
 therapeutic fusion proteins, is pleased to announce the appointment of
 Mr. William Rohn and Mr. Amit Sobti to the Company's Board of
"We are delighted to welcome Bill and Amit to help guide Protox through
 the exciting phase of the company's progress," said Dr. Fahar Merchant,
 President & CEO of Protox. "Their insights and experience with product
 commercialization and the capital markets from both the large
 pharmaceutical arena and the biotech industry will be invaluable. Their
 appointment is just another indication of our commitment to build and
 strengthen our board and to enhance our ability to move the company to
 the next level." 
Bill Rohn has over 30 years of experience as a senior executive in the
 pharmaceutical and biotech industry. He retired in January of 2005
 from the position of Chief Operating Officer at Biogen-Idec, a major
 global biotech company. He played an instrumental role in the $6.8
 billion merger of IDEC Pharmaceuticals and Biogen Inc. Prior to
 serving as COO of the combined company, Bill was the President and
 Chief Operating Officer of IDEC Pharmaceuticals where he helped
 transform IDEC from a small research organization into a very
 successful, biotechnology company. Before moving to the fledgling
 biotech industry, Bill spent approximately 25 years in the
 pharmaceutical sector in a variety of commercial operating roles of
 increasing responsibilities at Abbott Laboratories, Bristol-Myers
 Squibb Co., and Adria Laboratories (now part of Pfizer). In addition to
 his role at Protox, Bill serves on the Board of Directors of Cerus
 Corporation, Intellikine, Cebix Inc., and the La Jolla Institute of
 Allergy and Immunology. 
Amit Sobti is a principal with Warburg Pincus where he focuses on
 investments in healthcare. Prior to joining Warburg Pincus, he worked
 at Rhône Capital, a mid-market private equity firm, and at Merrill
 Lynch in the Mergers & Acquisitions group. Amit received an A.B. in
 Business Economics and an A.B. in Computer Science from Brown
 University. In addition to Protox, Amit also serves on the Board of
 Directors of ReSearch Pharmaceutical Services, Inc. 
About Protox
Protox Therapeutics is a leader in advancing novel, receptor targeted
 therapeutic fusion proteins. Two drug candidates derived from the
 company's INxin™ and PORxin™ platforms are in clinical development.
 Protox's lead program, PRX302 (PORxin), achieved positive results from
 its Phase 2b placebo controlled trial called TRIUMPH, to treat benign
 prostatic hyperplasia (BPH or enlarged prostate). Protox has partnered
 with Kissei Pharmaceuticals for the development and commercialization
 of PRX302 in Japan. PRX321 (INxin) is being developed for the treatment
 of various cancers and has received Fast Track Designation and Orphan
 Drug Status from the US FDA and EMEA for the treatment of primary brain
 cancer. For more information, please visit 
Certain statements included in this press release may be considered
 forward-looking. Such statements involve known and unknown risks,
 uncertainties and other factors that may cause actual results,
 performance or achievements to be materially different from those
 implied by such statements, and therefore these statements should not
 be read as guarantees of future performance or results. All
 forward-looking statements are based on Protox' current beliefs as well
 as assumptions made by and information currently available to Protox
 and relate to, among other things, anticipated financial performance,
 business prospects, strategies, regulatory developments, market
 acceptance and future commitments. Readers are cautioned not to place
 undue reliance on these forward-looking statements, which speak only as
 of the date of this press release. Due to risks and uncertainties,
 including the risks and uncertainties identified by Protox in its
 public securities filings; actual events may differ materially from
 current expectations. Protox disclaims any intention or obligation to
 update or revise any forward-looking statements, whether as a result of
 new information, future events or otherwise. 
To view this news release in HTML formatting, please use the following URL: 
For further information: <table border="0" valign="top"><tr><td>James Beesley<br/> Investor 
Relations<br/> Protox Therapeutics<br/> 604-813-0133<br/> <a 
href=""></a></td> <td></td> <td></td> 
<td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>Michael Moore<br/> Investor Relations<br/> 
Equicom Group<br/> 619-467-7067<br/> <a 
CO: Protox Therapeutics Inc.
ST: British Columbia
NI: MTC 2575 WNEWS  
-0- Feb/22/2011 12:00 GMT
Press spacebar to pause and continue. Press esc to stop.